Rosenberg M T
Mid-Michigan Health Centers, Jackson, MI 49201, USA.
Int J Clin Pract. 2007 Jul;61(7):1198-208. doi: 10.1111/j.1742-1241.2007.01418.x.
Recent advances in the management of erectile dysfunction (ED) involve the use of oral phosphodiesterase type-5 (PDE-5) inhibitor therapies which have transformed the perception of ED for both the patient and the healthcare provider. Recent treatment guidelines, including the American Urological Association (AUA) 2005 guidelines, promote a goal-oriented approach to therapy and emphasise that PDE-5 therapy should be offered to patients with ED as a first-line treatment option, unless contraindicated. Evidence-based studies have identified an association between ED and the presence of risk factors for cardiovascular and other vascular diseases, implicating ED as a marker for other vascular conditions. Therefore, the importance of screening and diagnosis in the primary care setting is paramount in the diagnosis and management of ED-associated comorbidities. This review provides an update on ED screening and management focusing on the use of PDE-5 inhibitor therapy in the primary care setting and also discusses clinical efficacy parameters with regard to recent results from clinical trials.
勃起功能障碍（ED）管理方面的最新进展包括使用口服5型磷酸二酯酶（PDE-5）抑制剂疗法，这改变了患者和医疗服务提供者对ED的认知。最近的治疗指南，包括美国泌尿外科学会（AUA）2005年指南，提倡采用以目标为导向的治疗方法，并强调对于ED患者，除非有禁忌证，PDE-5疗法应作为一线治疗选择提供给他们。基于证据的研究已确定ED与心血管及其他血管疾病危险因素的存在之间存在关联，这意味着ED是其他血管疾病的一个标志。因此，在初级保健环境中进行筛查和诊断对于ED相关合并症的诊断和管理至关重要。本综述提供了关于ED筛查和管理的最新情况，重点关注在初级保健环境中使用PDE-5抑制剂疗法，并讨论了关于近期临床试验结果的临床疗效参数。
